The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Mapping The Molecular Blueprint For Immune Cell Differentitation
Funder
National Health and Medical Research Council
Funding Amount
$753,300.00
Summary
Killer T cells are white blood cells that are key for helping control virus infections and in the recognition and elimination of cells that have become cancerous. This proposal aims to identify novel molecular mechanisms that control the ability of killer T cells to mediate their antiviral and anti-cancer functions. This will provide molecular targets for possible clinical interventions designed to either promote immunity (vaccination) or limit damage caused by T cell responses that target self
Determining The Causes And Consequences Of Epigenetic Remodelling In Cancer And Disease
Funder
National Health and Medical Research Council
Funding Amount
$863,413.00
Summary
The study of epigenetics and its role in gene control is proving to be the next major contributor to our future understanding and improvement of health outcomes. Professor Clark and her team are on a quest to unravel the secrets of human epigenome to help reduce the burden of human disease. Their research will help contribute to the discovery of genetic and epigenetic aberrations in cancer and other complex diseases with the development of new diagnostic tests and potential new epigenetic-based ....The study of epigenetics and its role in gene control is proving to be the next major contributor to our future understanding and improvement of health outcomes. Professor Clark and her team are on a quest to unravel the secrets of human epigenome to help reduce the burden of human disease. Their research will help contribute to the discovery of genetic and epigenetic aberrations in cancer and other complex diseases with the development of new diagnostic tests and potential new epigenetic-based therapies.Read moreRead less
A common characteristic of cancer is the failure of cells to die when they normally would. One of the problems with many cancer therapies is that they rely on the integrity of signalling pathways to the normal ‘death machinery’ of the cell to do their job. By understanding how the molecular death machine operates we are fashioning new drugs that can target it directly, thus bypassing the very pathways that are so frequently disrupted in tumour cells.
My research is aimed at understanding how the structure and dynamics of proteins dictates their function. I use X-ray crystallography to determine the shapes of proteins. Proteins are not static, however - they move in complicated ways, and often their motion is critical to their function (molecular motors, for example). It is very difficult to 'watch' this movement in the lab, so I use computer simulation to try to understand how proteins move.
Hepatitis C virus (HCV) and Human immunodeficiency virus (HIV) infect 200 million and 50 million people world-wide, respectively, and there are no preventative vaccines. The work outlined in this fellowship seeks to understand the structure and function of the major surface proteins of these viruses, their ability to be recognised by the immune system and to develop a novel vaccine for the prevention of HCV.
Structural Biology And Therapeutic Targeting Of Proteins Involved In Infection And Immunity
Funder
National Health and Medical Research Council
Funding Amount
$753,300.00
Summary
Structural biology plays an essential role in uncovering how proteins function at the molecular level, and further facilitates strategies to develop therapeutics targeting the diseases these proteins are involved in. In the proposed work, I will focus on bacterial virulence factors, to develop new antibiotics and vaccination strategies, and proteins involved in innate immunity pathways, to develop therapeutics against a number of associated disorders including chronic inflammatory diseases.
Peptides (mini proteins) have outstanding potential as new drugs for cancer, pain and many other diseases, but their potential has not been realised so far because peptides tend to be unstable in the body. I have discovered a new class of peptides that are ultra-stable and have very favourable pharmaceutical properties. I will use these peptides to develop a new generation of drugs that are more potent and with fewer side effects than traditional drugs.
Targeting The Unmet Global Medical Need Caused By Gram-negative 'superbugs': From Antibiotic Discovery To Novel Therapeutic Strategies
Funder
National Health and Medical Research Council
Funding Amount
$697,209.00
Summary
Bacterial ‘superbugs’ present a significant global medical challenge. ‘Old’ polymyxins are the only antibiotics against Gram-negative ‘superbugs’ but with limited pharmacological information available. In the next 5 years, as a pharmacologist I will continue re-developing polymyxins and discovering novel antibiotics against these problematic bacteria. My research targets the “Bad Bugs, No Drugs” disaster highlighted by the Infectious Diseases Society of America and the World Health Organization.